Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Yerel katalogda bu makaleye atıf yapan 11 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

1. 2025 Tolebrutinib in Nonrelapsing Secondary Progressive Multiple SclerosisAtıf 135 · OpenAlex
2. 2020 Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialAtıf 107 · OpenAlex
3. 2020 Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisAtıf 36 · OpenAlex
4. 2021 Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisAtıf 29 · OpenAlex
5. 2021 Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisAtıf 29 · OpenAlex
6. 2024 Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Atıf 21 · OpenAlex
7. 2023 Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisAtıf 10 · OpenAlex
8. 2024 Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential testAtıf 8 · OpenAlex
9. 2024 Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential testAtıf 6 · OpenAlex
10. 2023 Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomesAtıf 5 · OpenAlex